{"id":16484,"date":"2026-05-22T10:30:09","date_gmt":"2026-05-22T08:30:09","guid":{"rendered":"https:\/\/www.interpharma.ch\/?p=16484"},"modified":"2026-05-22T10:32:31","modified_gmt":"2026-05-22T08:32:31","slug":"communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal","status":"publish","type":"post","link":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal\/","title":{"rendered":"Communiqu\u00e9 de presse: Graves risques pour la prise en charge de la\u00a0population:\u00a0Interpharma rejette la r\u00e9vision de l\u2019OAMal"},"content":{"rendered":"\n

Interpharma rejette des points essentiels de la r\u00e9vision de l\u2019Ordonnance sur l\u2019assurance-maladie OAMal et de l\u2019OPAS pr\u00e9sent\u00e9e par le Conseil f\u00e9d\u00e9ral et s\u2019oppose enti\u00e8rement aux projets actuels. Ils ne tiennent pas compte des nouvelles conditions cadres internationales et risquent d\u2019affaiblir l\u2019acc\u00e8s aux traitements innovants ainsi que la comp\u00e9titivit\u00e9 de la place pharmaceutique suisse.<\/strong><\/p>\n\n\n\n

Du point de vue d\u2019Interpharma, les projets laissent \u00e0 d\u00e9sirer, car ils visent unilat\u00e9ralement une r\u00e9duction des co\u00fbts sans tenir compte raisonnablement de l\u2019impact sur la prise en charge des patient-e-s. D\u00e8s \u00e0 pr\u00e9sent, on observe en Suisse de nets retards d\u2019acc\u00e8s aux m\u00e9dicaments innovants et les mesures propos\u00e9es risquent d\u2019accentuer encore cette situation. En m\u00eame temps, des propositions de modernisation du syst\u00e8me de formation des prix concr\u00e8tes et praticables formul\u00e9es par l\u2019industrie n\u2019ont pas \u00e9t\u00e9 suffisamment prises en compte. Interpharma offre son concours et demande de poursuivre des discussions constructives entre toutes les parties impliqu\u00e9es pour remanier profond\u00e9ment les projets dans un contexte d\u2019ensemble coh\u00e9rent de politique de la sant\u00e9 qui aborde \u00e0 la fois la s\u00e9curit\u00e9 d\u2019approvisionnement, l\u2019innovation et la rentabilit\u00e9.<\/p>\n\n\n\n

Tenir compte des nouvelles conditions cadres internationales<\/strong><\/p>\n\n\n\n

Un point particuli\u00e8rement critique est le fait que les projets font l\u2019impasse sur les modifications consid\u00e9rables des conditions cadres internationales: de nouvelles \u00e9volutions de la politique mondiale en mati\u00e8re de prix des m\u00e9dicaments, en particulier le fait que les \u00c9tats-Unis incluent la Suisse en tant que pays de r\u00e9f\u00e9rence pour fixer leurs prix, accroissent la pression sur la disponibilit\u00e9 de traitements innovants pour la population. \u00c0 moins d\u2019une r\u00e9orientation strat\u00e9gique, les nouveaux m\u00e9dicaments risquent de ne plus arriver aux patient-e-s qu\u2019avec du retard, voire plus du tout.<\/p>\n\n\n\n

En outre, les projets de r\u00e9visions sont pr\u00e9sent\u00e9s sans attendre de disposer des travaux et conclusions du groupe de travail \u00abplace \u00e9conomique Life Science\u00bb institu\u00e9 par le Conseil f\u00e9d\u00e9ral et de les prendre syst\u00e9matiquement en compte. Or, ce groupe de travail a explicitement pour mission de se pencher sur les d\u00e9fis de prise en charge des patient-e-s en Suisse. Interpharma demande donc un temps d\u2019arr\u00eat et une r\u00e9orientation strat\u00e9gique pour harmoniser \u00e0 long terme la ma\u00eetrise des co\u00fbts, l\u2019acc\u00e8s rapide des patient-e-s et le renforcement de la place suisse dans le domaine des sciences de la vie.<\/p>\n\n\n\n

Notre consultation (en allemand)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Interpharma rejette des points essentiels de la r\u00e9vision de l\u2019Ordonnance sur l\u2019assurance-maladie OAMal et de l\u2019OPAS pr\u00e9sent\u00e9e par le Conseil f\u00e9d\u00e9ral et s\u2019oppose enti\u00e8rement aux projets actuels. Ils ne tiennent pas compte des nouvelles conditions cadres internationales et risquent d\u2019affaiblir l\u2019acc\u00e8s aux traitements innovants ainsi que la comp\u00e9titivit\u00e9 de la place pharmaceutique suisse. Du point […]<\/p>\n","protected":false},"author":7,"featured_media":16483,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"tags":[127,178,179],"class_list":["post-16484","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","tag-acces-des-patients","tag-medienmitteilung","tag-medikamentenmarkt"],"acf":[],"yoast_head":"\nCommuniqu\u00e9 de presse: Graves risques pour la prise en charge de la\u00a0population:\u00a0Interpharma rejette la r\u00e9vision de l\u2019OAMal - Interpharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Communiqu\u00e9 de presse: Graves risques pour la prise en charge de la\u00a0population:\u00a0Interpharma rejette la r\u00e9vision de l\u2019OAMal\" \/>\n<meta property=\"og:description\" content=\"Interpharma rejette des points essentiels de la r\u00e9vision de l\u2019Ordonnance sur l\u2019assurance-maladie OAMal et de l\u2019OPAS pr\u00e9sent\u00e9e par le Conseil f\u00e9d\u00e9ral et s\u2019oppose enti\u00e8rement aux projets actuels. Ils ne tiennent pas compte des nouvelles conditions cadres internationales et risquent d\u2019affaiblir l\u2019acc\u00e8s aux traitements innovants ainsi que la comp\u00e9titivit\u00e9 de la place pharmaceutique suisse. Du point […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal\/\" \/>\n<meta property=\"og:site_name\" content=\"Interpharma\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-22T08:30:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-22T08:32:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/02\/blog-image-053-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"lukaskuemmerli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:site\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"lukaskuemmerli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal\/\"},\"author\":{\"name\":\"lukaskuemmerli\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/2854d813965ba4a7feaeffbe96f8eadf\"},\"headline\":\"Communiqu\u00e9 de presse: Graves risques pour la prise en charge de la\u00a0population:\u00a0Interpharma rejette la r\u00e9vision de l\u2019OAMal\",\"datePublished\":\"2026-05-22T08:30:09+00:00\",\"dateModified\":\"2026-05-22T08:32:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal\/\"},\"wordCount\":454,\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/02\/blog-image-053-scaled.jpg\",\"keywords\":[\"Acc\u00e8s des patients\",\"Medienmitteilungen\",\"Medikamentenmarkt\"],\"inLanguage\":\"fr-FR\",\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal\/\",\"url\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal\/\",\"name\":\"Communiqu\u00e9 de presse: Graves risques pour la prise en charge de la\u00a0population:\u00a0Interpharma rejette la r\u00e9vision de l\u2019OAMal - Interpharma\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/02\/blog-image-053-scaled.jpg\",\"datePublished\":\"2026-05-22T08:30:09+00:00\",\"dateModified\":\"2026-05-22T08:32:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal\/#primaryimage\",\"url\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/02\/blog-image-053-scaled.jpg\",\"contentUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/02\/blog-image-053-scaled.jpg\",\"width\":2560,\"height\":1707,\"caption\":\"Bundeshaus Bern, Schweiz\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/www.interpharma.ch\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Communiqu\u00e9 de presse: Graves risques pour la prise en charge de la\u00a0population:\u00a0Interpharma rejette la r\u00e9vision de l\u2019OAMal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.interpharma.ch\/#website\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"name\":\"Interpharma\",\"description\":\"Verband der forschenden Pharmazeutischen Firmen\",\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.interpharma.ch\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.interpharma.ch\/#organization\",\"name\":\"Interpharma\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"contentUrl\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"width\":\"1200\",\"height\":\"1200\",\"caption\":\"Interpharma\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/interpharma_ch\",\"https:\/\/ch.linkedin.com\/company\/interpharma\",\"https:\/\/www.instagram.com\/interpharma_ch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/2854d813965ba4a7feaeffbe96f8eadf\",\"name\":\"lukaskuemmerli\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/c3bfeac2b6c479264ad184573779a451a81113f9e7cbabe607006461ca783d10?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/c3bfeac2b6c479264ad184573779a451a81113f9e7cbabe607006461ca783d10?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/c3bfeac2b6c479264ad184573779a451a81113f9e7cbabe607006461ca783d10?s=96&d=mm&r=g\",\"caption\":\"lukaskuemmerli\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Communiqu\u00e9 de presse: Graves risques pour la prise en charge de la\u00a0population:\u00a0Interpharma rejette la r\u00e9vision de l\u2019OAMal - Interpharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal\/","og_locale":"fr_FR","og_type":"article","og_title":"Communiqu\u00e9 de presse: Graves risques pour la prise en charge de la\u00a0population:\u00a0Interpharma rejette la r\u00e9vision de l\u2019OAMal","og_description":"Interpharma rejette des points essentiels de la r\u00e9vision de l\u2019Ordonnance sur l\u2019assurance-maladie OAMal et de l\u2019OPAS pr\u00e9sent\u00e9e par le Conseil f\u00e9d\u00e9ral et s\u2019oppose enti\u00e8rement aux projets actuels. Ils ne tiennent pas compte des nouvelles conditions cadres internationales et risquent d\u2019affaiblir l\u2019acc\u00e8s aux traitements innovants ainsi que la comp\u00e9titivit\u00e9 de la place pharmaceutique suisse. Du point […]","og_url":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal\/","og_site_name":"Interpharma","article_published_time":"2026-05-22T08:30:09+00:00","article_modified_time":"2026-05-22T08:32:31+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/02\/blog-image-053-scaled.jpg","type":"image\/jpeg"}],"author":"lukaskuemmerli","twitter_card":"summary_large_image","twitter_creator":"@interpharma_ch","twitter_site":"@interpharma_ch","twitter_misc":{"\u00c9crit par":"lukaskuemmerli","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal\/#article","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal\/"},"author":{"name":"lukaskuemmerli","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/2854d813965ba4a7feaeffbe96f8eadf"},"headline":"Communiqu\u00e9 de presse: Graves risques pour la prise en charge de la\u00a0population:\u00a0Interpharma rejette la r\u00e9vision de l\u2019OAMal","datePublished":"2026-05-22T08:30:09+00:00","dateModified":"2026-05-22T08:32:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal\/"},"wordCount":454,"publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"image":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/02\/blog-image-053-scaled.jpg","keywords":["Acc\u00e8s des patients","Medienmitteilungen","Medikamentenmarkt"],"inLanguage":"fr-FR","copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/www.interpharma.ch\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal\/","url":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal\/","name":"Communiqu\u00e9 de presse: Graves risques pour la prise en charge de la\u00a0population:\u00a0Interpharma rejette la r\u00e9vision de l\u2019OAMal - Interpharma","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal\/#primaryimage"},"image":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/02\/blog-image-053-scaled.jpg","datePublished":"2026-05-22T08:30:09+00:00","dateModified":"2026-05-22T08:32:31+00:00","breadcrumb":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal\/#primaryimage","url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/02\/blog-image-053-scaled.jpg","contentUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/02\/blog-image-053-scaled.jpg","width":2560,"height":1707,"caption":"Bundeshaus Bern, Schweiz"},{"@type":"BreadcrumbList","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-graves-risques-pour-la-prise-en-charge-de-la-population-interpharma-rejette-la-revision-de-loamal\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.interpharma.ch\/fr\/"},{"@type":"ListItem","position":2,"name":"Communiqu\u00e9 de presse: Graves risques pour la prise en charge de la\u00a0population:\u00a0Interpharma rejette la r\u00e9vision de l\u2019OAMal"}]},{"@type":"WebSite","@id":"https:\/\/www.interpharma.ch\/#website","url":"https:\/\/www.interpharma.ch\/","name":"Interpharma","description":"Verband der forschenden Pharmazeutischen Firmen","publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.interpharma.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.interpharma.ch\/#organization","name":"Interpharma","url":"https:\/\/www.interpharma.ch\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/","url":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","contentUrl":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","width":"1200","height":"1200","caption":"Interpharma"},"image":{"@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/interpharma_ch","https:\/\/ch.linkedin.com\/company\/interpharma","https:\/\/www.instagram.com\/interpharma_ch\/"]},{"@type":"Person","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/2854d813965ba4a7feaeffbe96f8eadf","name":"lukaskuemmerli","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/c3bfeac2b6c479264ad184573779a451a81113f9e7cbabe607006461ca783d10?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/c3bfeac2b6c479264ad184573779a451a81113f9e7cbabe607006461ca783d10?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c3bfeac2b6c479264ad184573779a451a81113f9e7cbabe607006461ca783d10?s=96&d=mm&r=g","caption":"lukaskuemmerli"}}]}},"_links":{"self":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/16484","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/comments?post=16484"}],"version-history":[{"count":3,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/16484\/revisions"}],"predecessor-version":[{"id":16496,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/16484\/revisions\/16496"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/media\/16483"}],"wp:attachment":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/media?parent=16484"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/tags?post=16484"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}